A clinical stage biopharmaceutical company focused on developing therapeutics for autoimmune-driven inflammatory diseases

Eliem Therapeutics, following the close of the acquisition of Tenet Medicines, will be focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy.

Our Pipeline

Budoprutug, an anti-CD19 mAb, is designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. This reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as SLE, ITP and MN. In a Phase 1b clinical trial of budoprutug in MN, 3 out of 5 (or 60%) of patients that received four doses of budoprutug achieved a complete remission of proteinuria, a primary symptom of MN.

In SLE, one of budoprutug’s lead indications, the underlying pathology involves production of autoantibodies by autoreactive B cells that contribute to inflammation and tissue damage. Because budoprutug is designed to target and deplete CD19-expressing B cells known to produce autoantibodies, the Company believes budoprutug has the potential to treat SLE.

In ITP, the Company believes targeting plasmablasts and plasma cells is likely to decrease the production of autoantibodies, increase platelet count and ameliorate disease. B cell depletion with anti-CD20 targeting mAbs, has demonstrated efficacy in some patients with ITP based on in clinical trials conducted by third parties. For those patients who do not respond to anti-CD20 therapy, the Company believes an anti-CD19 approach, such as budoprutug, may have the ability to further deplete pathogenic CD20-/CD19+ cells.

Our Experienced Team

Leadership Team
Board of Directors
Aoife Brennan
Aoife Brennan, M.B., Ch.B.
President and Chief Executive Officer
Jan_Hillson
Jan Hillson, M.D.
Senior Clinical Advisor
Brett Kaplan Headshot
Brett Kaplan, M.D.
Chief Operating Officer
Emily_Pimblett
Emily Pimblett
Chief Accounting Officer
Nishi Headshot
Nishi Rampal, M.D.
Senior Vice President, Clinical Development
Andrew Levin, M.D., Ph.D.
(Chairman)
Aoife Brennan
Aoife Brennan, M.B., Ch.B.
Judith Dunn, Ph.D.
Liam Ratcliffe, M.D., Ph.D.
Adam Rosenberg
Simon Tate
Stephen_Thomas
Stephen Thomas, Ph.D.

News

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below. Guggenheim Securities Healthcare Innovation Conference Format: Fireside chat and

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trial s in Systemic Lupus Erythematosus (SLE) and Immune
Load More

Careers

We are always looking to grow our team and believe it takes teamwork, trust and tenacity to deliver on the promise of helping patients live happier, more fulfilling lives. If this sounds like you, please indicate which position you are interested in and contact us at Careers US or Careers UK.

We’d love to connect.

Open Positions
Sorry, there are currently no open positions available. Please check back soon!
Sorry, there are currently no open positions available. Please check back soon!
Sorry, there are currently no open positions available. Please check back soon!

Contact Us

MEDIA
INVESTOR RELATIONS
HUMAN RESOURCES
PARTNERING
Eliem Therapeutics, Inc.
PMB #117
2801 Centerville Road, 1st Floor
Wilmington, DE 19808-1609

Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT